Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 6—June 2011

Salmonella enterica Serotype Typhi with Nonclassical Quinolone Resistance Phenotype

Marie Accou-Demartin, Valérie Gaborieau, Yajun Song, Philippe Roumagnac, Bruno Marchou, Mark Achtman, and François-Xavier WeillComments to Author 
Author affiliations: Author affiliations: Institut Pasteur, Paris, France (M. Accou-Demartin, F.-X. Weill); Hôpital Purpan, Toulouse, France (V. Gaborieau, B. Marchou); University College Cork, Cork, Ireland (Y. Song, M. Achtman); Centre de Coopération International en Recherche Agronomique pour le Développement, Montpellier, France (P. Roumagnac)

Main Article

Table 1

Characteristics of the 674 Salmonella enterica serovar Typhi isolates belonging to subpopulations A, C, and D, France, 2007–2009*

No. isolates
Nal MICs,† μg/mL
Cip MICs,† μg/mL QRDR mutation (no./no. tested)
A 554 4 4 1–8 0.008 0.025 0.002–0.08 WT (75/77)
gyrB Leu465 (2/77)
C 119 >256 >256 128–>256 0.25 0.5 0.06–0.5 gyrA Phe83 (24/44)
gyrA Tyr83 (12/44)
gyrA Asn87 (4/44)
gyrA Gly87 (2/44)
gyrA Phe83 and parE Asn420 (2/44)
D 1 >256 8 gyrA Phe83, gyrA Asn87, and parC Ile80

*Nal, nalidixic acid; Cip, ciprofloxacin; QRDR, quinolone resistance–determining region of the gyrA, gyrB, parC, and parE genes; WT, wild type.
†MICs of Nal and Cip were determined by Etest strips. MIC50, 50% below; MIC90, 90% below.


Main Article

Page created: August 03, 2011
Page updated: August 03, 2011
Page reviewed: August 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.